Abstract: The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.

Abstract: A system for collaborative video recording is described. The system may include a reference clock configured to track a reference time. The system may provide, to a plurality of recording devices, a synchronization code for a collaborative video recording session. The system may identify the plurality of recording devices as participants in the collaborative video recording session. The collaborative video recording session may include broadcasting one or more synchronization signals to synchronize the plurality of recording devices to the reference time tracked by the reference clock. The collaborative video recording session may include receiving a plurality of videos from the plurality of recording devices, wherein the plurality of videos comprise timestamps based on synchronization to the reference time. The collaborative video recording session may include generating a shared timeline for the plurality of videos, wherein the shared timeline synchronizes the timestamps between the plurality of videos.

Abstract: Provided herein are methods and uses involving the combination of an anti-CD20 antibody, e.g., rituximab with a protein therapeutic, for example, an antibody (e.g., an antibody that specifically binds to human CD47).

Abstract: Techniques for tracking an evacuation of a location in an environment that utilizes physical tokens to prove physical presence at the location are presented. The techniques include receiving data representing of subordinates of an evacuation facilitator; receiving physical token based location status information for at least one of the subordinates, where the physical token based location status information is based on electronic readings of the physical tokens; determining based on the physical token based location status information, a physical presence status at the location for the at least one of the subordinates; receiving evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location; and recording the evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location.

Abstract: Techniques for tracking an evacuation of a location in an environment that utilizes physical tokens to prove physical presence at the location are presented. The techniques include receiving data representing of subordinates of an evacuation facilitator; receiving physical token based location status information for at least one of the subordinates, where the physical token based location status information is based on electronic readings of the physical tokens; determining based on the physical token based location status information, a physical presence status at the location for the at least one of the subordinates; receiving evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location; and recording the evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location.

Abstract: Provided herein are antibodies and antigen-binding fragments thereof with low or no immunogenicity in humans and optionally with desirable manufacturing properties. Also provided are compositions comprising such antibodies or antigen-binding fragments, methods of using such antibodies, and methods for making such antibodies.

Abstract: Techniques for tracking an evacuation of a location in an environment that utilizes physical tokens to prove physical presence at the location are presented. The techniques include receiving data representing of subordinates of an evacuation facilitator; receiving physical token based location status information for at least one of the subordinates, where the physical token based location status information is based on electronic readings of the physical tokens; determining based on the physical token based location status information, a physical presence status at the location for the at least one of the subordinates; receiving evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location; and recording the evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location.

Abstract: Techniques for tracking an evacuation of a location in an environment that utilizes physical tokens to prove physical presence at the location are presented. The techniques include receiving data representing of subordinates of an evacuation facilitator; receiving physical token based location status information for at least one of the subordinates, where the physical token based location status information is based on electronic readings of the physical tokens; determining based on the physical token based location status information, a physical presence status at the location for the at least one of the subordinates; receiving evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location; and recording the evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location.

Abstract: Techniques for tracking an evacuation of a location in an environment that utilizes physical tokens to prove physical presence at the location are presented. The techniques include receiving data representing of subordinates of an evacuation facilitator; receiving physical token based location status information for at least one of the subordinates, where the physical token based location status information is based on electronic readings of the physical tokens; determining based on the physical token based location status information, a physical presence status at the location for the at least one of the subordinates; receiving evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location; and recording the evacuation status information for each of the at least one of the subordinates that has a physical presence status that indicates a presence at the location.

Abstract: A computer implemented technique of tracking an evacuation of a location in an environment that utilizes physical tokens to prove physical presence at the location is presented.

Abstract: Provided herein are methods and uses involving the combination of an anti-CD20 antibody, e.g., rituximab with a protein therapeutic, for example, an antibody (e.g., an antibody that specifically binds to human CD47).

Abstract: A computer implemented technique of tracking an evacuation of a location in an environment that utilizes physical tokens to prove physical presence at the location is presented.

Abstract: Provided herein are antibodies and antigen-binding fragments thereof with low or no immunogenicity in humans and optionally with desirable manufacturing properties. Also provided are compositions comprising such antibodies or antigen-binding fragments, methods of using such antibodies, and methods for making such antibodies.

Abstract: There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of tRNAPyl expression on cell viability and/or cell growth is reduced or eliminated.

Abstract: There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of tRNAPyl expression on cell viability and/or cell growth is reduced or eliminated.

Abstract: There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of tRNAPyl expression on cell viability and/or cell growth is reduced or eliminated.

Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.